focus -WSS

focus

author：entertainment 2025-09-09 19:27:49 - browse：39537

Bernard Moss, a research scientist at NIAID. -- Infectious disease coverage from STAT — Bernard Moss Courtesy NIAID

For more than half a century, scientist Bernard Moss has been commanding the attention of peers interested in prying biological secrets from poxviruses and other microbiological targets. Now he’s commanding the attention of a different audience: House Republicans.

Moss, who will mark his 86th birthday in late July and who goes by Bernie, has worked for more than 55 years in the laboratories of the National Institute of Allergy and Infectious Diseases in Bethesda, Md. Over that time, he has been investigating viruses in relative anonymity — except, that is, among the virological cognoscenti.

But last year, in an interview with Science, Moss said he planned to try to determine why one strain of mpox viruses, known as Clade 1, is so much more virulent than those in a second strain, Clade 2, by taking genes from the former and putting them into the latter. Clade 2 viruses are responsible for the ongoing mpox outbreak first detected in May 2022.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： H5N1 bird flu: what we're starting to learn about infection in cows

leisure time

WSS

Readout LOUD podcast: brain research, obesity drug sales, Novartis

White House touts steps to stem shortages of cancer treatments

Sanofi strikes deal with Novavax, boosting the vaccine maker

It shouldn't be easy to buy synthetic DNA to recreate a deadly virus

Elevance, private equity launch primary care company

Alcohol isn't healthy after all. Will new dietary guidelines reflect that?

focus

focus

hotspot

Hollywood unions extend contract negotiations for actors

Software glitch causes Tandem insulin pump to shutdown, FDA warns

Medical records are filled with copy

Steward Health Care files for bankruptcy

FDA approval of Sarepta Duchenne genetic therapy gives me hope

After gene therapy, two congenitally deaf children hear for the first time

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Making AI in medicine accessible to smaller, and rural hospitals

Novavax promises a turnaround & Lilly roils the obesity market

Readout LOUD podcast: What to know about H5N1 bird flu

knowledge

Nick Leschly quits Bluebird Bio spinout amid restructuring, layoffs

IRA could hurt research into orphan drugs for rare diseases

How medical schools plan to diversify without affirmative action

Walmart eyes Medicare Advantage provider ChenMed

New weight loss drugs vying to be the next Wegovy or Mounjaro

How medical schools plan to diversify without affirmative action

knowledge

entertainment

leisure time

focus